




PHARMACEUTICAL 2018

Oncolix Inc.
Rank 323 of 342





PHARMACEUTICAL 2018

Oncolix Inc.
Rank 323 of 342

The relative strengths and weaknesses of Oncolix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncolix Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Oncolix Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 215% points.

The company's Economic Capital Ratio, given in the ranking table, is -361%, being 407% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	889
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,263
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,841
Other Liabilities	1,268
Other Net Income	437
Other Revenues	0
Property and Equipment	0
Research and Development	463
Selling, General and Administrative Expense	1,490

Output Variable	Value in 1000 USD
Assets	889
Liabilities	2,531
Expenses	3,794
Revenues	0
Stockholders Equity	-1,642
Net Income	-3,357
Comprehensive Net Income	-3,357
Economic Capital Ratio	-361%